The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

INR:8984. rummy diya download "Pharmaceutical Quick Reading Club" Wuhan's first square cabin hospital began to treat patients Merck and GSK will be split APL ...

Gaming corps logo winner bet online registration 80% of patients with BRCA mutations responded! Olaparib treatment of p ...

Topmarks money coln game onllne These varieties have been included in the centralized procurement and many places have started pilot pro ...

ekart delivery National Health Commission: The overall national epidemic situation is on a downward trend ICH approves S11 guidelines for nonclinical safety testing of pediatric drugs 80% of patients ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

“These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible ...